Eagle's Eye View: Your Weekly CV Update From ACC.org

In this week's View, Dr. Eagle looks at a collaborative analysis of three randomized trials that investigated inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy. He then covers the 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure with Preserved Ejection Fraction. Finally, Dr. Eagle explores ACTIVE-AF, a randomized controlled trial on exercise and physical activity program in patients with atrial fibrillation. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses the value of the balloon pulmonary angioplasty procedure for patients with chronic thromboembolic pulmonary hypertension. He then reviews the sub analysis of the HOST EXAM trial assessing the benefit of aspirin versus clopidogrel as a maintenance strategy after coronary stenting. Finally, Dr. Eagle explores the BIOVASC trial weighing in on immediate versus staged complete revascularization in patients presenting with acute coronary syndrome and multivessel coronary disease. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Deepak Bhatt sits in for Dr. Eagle and discusses heart failure following anti-inflammatory medications in patients with type 2 diabetes mellitus, then looks at the results of the ARCHITECT Study concerning alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia. Finally, Dr. Bhatt explores a state-of-the-art review of the benefits of exercise in cardiovascular diseases, from mechanisms to clinical implementation. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Deepak Bhatt discusses a three-decade exploration from the Aortic Institute at Yale University on the rate of the unoperated ascending thoracic aortic aneurysm. He then looks at the final study report of andexanet alfa for major bleeding with factor Xa inhibitors. Finally, Dr. Bhatt explores subclinical coronary atherosclerosis and risk for myocardial infarction in a Danish cohort. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses implantable defibrillator system shock function, mortality, and cause of death after magnetic resonance imaging. He then explores the association of preoperative medical consultation with a reduction in adverse postoperative outcomes and use of processes of care. Finally, Dr. Eagle explores a comprehensive analysis of a multicenter registry that examined the prognostic implications of discordant low-gradient severe aortic stenosis. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses the incidence of cardiac arrest during sports among women versus men, then looks at a scientific statement from the American Heart Association on atrial fibrillation occurring during acute hospitalization. Finally, Dr. Eagle explores the results reported in the RACING Trial that addressed the use of moderate-intensity statins with ezetimibe vs. high-intensity statins in patients with diabetes and atherosclerotic cardiovascular disease. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses a prespecified analysis of the NUDGE-FLU trial that reported on the effectiveness of electronic nudges on influenza vaccination rate in older adults with cardiovascular disease, then looks at a comparison of the ESC/EACTS vs. ACC/AHA guidelines for the management of severe aortic stenosis. Finally, Dr. Eagle explores a long-term study of pregnancy complications and long-term mortality in a diverse cohort. Subscribe to Eagle’s Eye View

Dr. Deepak Bhatt reviews the Day 3 late-breaking science from ACC.23, including FREEDOM COVID ANTICOAG (0:52), STELLAR Phase III (1:49), and PULSED AF (2:49). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation. Subscribe to Eagle’s Eye View

Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from ACC.23, including BIOVASC (0:39), UK MINI MITRAL (2:12), and BETTER CARE HF (4:15). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using the hashtag #ACC23 to join the conversation. Subscribe to Eagle’s Eye View

Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from ACC.23, including CLEAR OUTCOMES (0:41), TRILUMINATE (2:35) and STOP CA (5:25). The ACC is providing coverage of the hottest ACC.23 science. For trial summaries, news coverage, daily video wrap-ups and more, visit ACC's Meeting Coverage page and follow the ACC on social media using #ACC23 to join the conversation.

In this week’s View, Dr. Eagle discusses Lp(a) as a main driver for the risk of ASCVD, MI, and aortic valve stenosis independent of CRP. This article is timely as we continue to attempt to lower the risks with ongoing trials currently working on relevant therapeutic options for lowering Lp(a). Then Dr. Eagle looks at women with CHD and mild PH who appear to have better pregnancy outcomes as compared with those with moderate-to-severe PH. Finally, Dr. Eagle explores the PARTNER Trials and its insights concerning cardiac damage and quality of life after Aortic Valve Replacement. We are looking forward to continuing to engage you during ACC.23 (March 4-6) in this formidable time of education! Check back for further updates! Subscribe to Eagle’s Eye View

Cardiovascular professionals are coming together for ACC.23 in New Orleans, March 4-6, to learn the latest practice-changing breakthrough research and trials results from around the world. In this View episode, guest host Deepak Bhatt MD, MPH, FACC, offers a preview of some of the hottest trials at ACC.23. Kicking us off on Day 1, Saturday, March 4, we will hear the positive outcomes from the CLEAR OUTCOMES trial and the favorable data for structural heart disease coming out of the TRILUMINATE trial. Day 2, Sunday, March 5, can’t be missed! Among the many presentations: UK MINI MITRAL weighs the minimally invasive approach versus conventional sternotomy for mitral valve repair surgery and the RENOVATE COMPLEX PCI trial that examines intravascular imaging-guided versus angiography-guided procedural optimization in complex percutaneous coronary intervention – a subject of particular interest to interventionalists. And that’s just the beginning: the 5-year final results from the COAPT trial are in; the 3-year outcomes from the EVOLUT low risk trial sound positive and continue to be in favor of TAVR; the BIOVASC trial data will be released, and it’s likely the findings will continue to be in favor of complete revascularization strategies in patients presenting with acute coronary syndromes and multivessel coronary disease. On Monday, the last day of the conference, Dr. Valentin Fuster will present the FREEDOM COVID ANTICOAG trial, discussing anticoagulation strategies in non-critically ill hospitalized COVID patients. Next up, the STELLAR trial, a study of sotatercept in combination with background therapy for the treatment of pulmonary arterial hypertension, will be presented. And finally, the findings of the collaborative analysis of participants in the three major trials are also scheduled: the PROMINENT, REDUCE-IT, STRENGTH trials. Be sure to check back on Eagle's Eye View throughout the meeting for further updates. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses a clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions on renal denervation in the management of hypertension in adults, then looks at the risk of surgical mitral valve repair for primary mitral regurgitation. Finally, Dr. Eagle explores an observational study that examines primary prevention of acute cardiovascular events by influenza vaccination. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses the recent expert panel statement on positron emission tomography (PET) for assessment of coronary microvascular dysfunction, then looks at the impact of transcatheter mitral valve repair availability on the volume and outcomes of surgical repair. Finally, Dr. Eagle explores the 2023 ACC/AHA/SCAI Advanced Training Statement on Interventional Cardiology. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions, then looks at practical approaches to genetic screening in cardiomyopathies. Finally, Dr. Eagle explores long-term outcomes of perioperative myocardial infarction or injury after non-cardiac surgery. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses the ACC Expert Consensus Documents on comprehensive multidisciplinary care for the patient with cardiac amyloidosis, then looks at findings from the SPRINT Trial on the effect of intensive blood pressure control on troponin and natriuretic peptide levels. Finally, Dr. Eagle explores early extracorporeal CPR for refractory out-of-hospital cardiac arrest compared to traditional CPR. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses recurrent venous thromboembolism and bleeding with extended anticoagulation and the VTE-PREDICT risk score, then looks at infective endocarditis after transcatheter aortic valve replacement (TAVR). Finally, Dr. Eagle explores aspirin and low-molecular-weight heparin for thromboprophylaxis after a fracture. Subscribe to Eagle’s Eye View

In this week’s View, Dr. Eagle discusses the treatment of radiation-induced aortic stenosis, then looks at PCSK9 inhibition during the inflammatory stage of SARS-CoV-2 infection. Finally, Dr. Eagle explores myocardial injury on CMR in patients with COVID-19 and suspected cardiac involvement. Subscribe to Eagle’s Eye View https://twitter.com/keaglemd https://twitter.com/accintouch?lang=en

In this week’s View, Dr. Eagle discuses heart failure drug treatment - inertia, titration and discontinuation as analyzed in EVOLUTION HF, a multinational observational study, then looks at Non-Obstructive Coronary Arteries (INOCA), and insights gained from the ISCHEMIA Trial. Finally, Dr. Eagle explores findings regarding exercise volume versus intensity and the progression of coronary atherosclerosis in middle-aged and older athletes from the MARC-2 Study. Subscribe to Eagle’s Eye View

Top Clinical Trials It was another great year for trial coverage on ACC.org! There were almost 140,000 unique views of the top 10 trials and top 10 trial updates for the year. Treatment of heart failure and of hypertrophic cardiomyopathy were hot topics. In addition to covering new trials, we updated prior trials with any related significant presentations or publications. We have added new features for our learners to make clear what is updated compared with the prior version of a clinical trial summary. Hopefully, this change allows quicker reading of these trial synopses. Interestingly, some of the trial updates had more views than de novo trial coverage. We have also started providing visual abstracts for some of the key trials at the major meetings. We are striving to make ACC.org a very user-friendly educational portal. On behalf of the ACC.org staff, Happy Holidays and a joyous New Year to you all! Deepak L. Bhatt, MD, MPH, FACC Senior Associate Editor, Clinical Trials and News, ACC.org Subscribe to Eagle’s Eye View